» Articles » PMID: 20826898

The Biological Effectiveness of Targeted Radionuclide Therapy Based on a Whole-body Pharmacokinetic Model

Overview
Journal Phys Med Biol
Publisher IOP Publishing
Date 2010 Sep 10
PMID 20826898
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Biologically effective dose (BED) may be more of a relevant quantity than absorbed dose for establishing tumour response relationships. By taking into account the dose rate and tissue-specific parameters such as repair and radiosensitivity, it is possible to compare the relative biological effects of different targeted radionuclide therapy (TRT) agents. The aim of this work was to develop an analytical tumour BED calculation for TRT that could predict a relative biological effect based on normal body and tumour pharmacokinetics. This work represents a step in the direction of establishing relative pharmacokinetic criteria of when the BED formalism is more applicable than absorbed dose for TRT. A previously established pharmacokinetic (PK) model for TRT was used and adapted into the BED formalism. An analytical equation for the protraction factor, which incorporates dose rate and repair rate, was derived. Dose rates within the normal body and tumour were related to the slopes of their time-activity curves which were determined by the ratios of their respective PK parameters. The relationships between the tumour influx-to-efflux ratio (k(34):k(43)), central compartment efflux-to-influx ratio (k(12):k(21)), central elimination (k(el)), and tumour repair rate (μ), and tumour BED were investigated. As the k(34):k(43) ratio increases and the k(12):k(21) ratio decreases, the difference between tumour BED and D increases. In contrast, as the k(34):k(43) ratios decrease and the k(12):k(21) ratios increase, the tumour BED approaches D. At large k(34):k(43) ratios, the difference between tumour BED and D increases to a maximum as k(el) increases. At small k(34):k(43) ratios, the tumour BED approaches D at very small k(el). At small μ and small k(34):k(43) ratios, the tumour BED approaches D. For large k(34):k(43) ratios, large μ values cause tumour BED to approach D. This work represents a step in the direction of establishing relative PK criteria of when the BED formalism is more applicable than absorbed dose for TRT. It also provides a framework by which the biological effects of different TRT agents can be compared in order to predict efficacy.

Citing Articles

Murine-specific Internal Dosimetry for Preclinical Investigations of Imaging and Therapeutic Agents.

Bednarz B, Grudzinski J, Marsh I, Besemer A, Baiu D, Weichert J Health Phys. 2018; 114(4):450-459.

PMID: 29481536 PMC: 5831541. DOI: 10.1097/HP.0000000000000789.


Integrated PK-PD and agent-based modeling in oncology.

Wang Z, Butner J, Cristini V, Deisboeck T J Pharmacokinet Pharmacodyn. 2015; 42(2):179-89.

PMID: 25588379 PMC: 4985529. DOI: 10.1007/s10928-015-9403-7.


Chemoradionuclide therapy with 186re-labeled liposomal doxorubicin: toxicity, dosimetry, and therapeutic response.

Soundararajan A, Bao A, Phillips W, McManus L, Goins B Cancer Biother Radiopharm. 2011; 26(5):603-14.

PMID: 21834653 PMC: 3189008. DOI: 10.1089/cbr.2010.0948.

References
1.
Wessels B, Meares C . Physical and chemical properties of radionuclide therapy. Semin Radiat Oncol. 2000; 10(2):115-22. DOI: 10.1016/s1053-4296(00)80048-x. View

2.
Bodey R, Evans P, Flux G . Application of the linear-quadratic model to combined modality radiotherapy. Int J Radiat Oncol Biol Phys. 2004; 59(1):228-41. DOI: 10.1016/j.ijrobp.2003.12.031. View

3.
Grudzinski J, Burnette R, Weichert J, Jeraj R . Dosimetric effectiveness of targeted radionuclide therapy based on a pharmacokinetic landscape. Cancer Biother Radiopharm. 2010; 25(4):417-26. PMC: 3787722. DOI: 10.1089/cbr.2009.0754. View

4.
Yang Y, Xing L . Optimization of radiotherapy dose-time fractionation with consideration of tumor specific biology. Med Phys. 2006; 32(12):3666-77. DOI: 10.1118/1.2126167. View

5.
Roberson P, Buchsbaum D . Reconciliation of tumor dose response to external beam radiotherapy versus radioimmunotherapy with 131iodine-labeled antibody for a colon cancer model. Cancer Res. 1995; 55(23 Suppl):5811s-5816s. View